Protein Design Labs Incorporated

Protein Design Labs Inc. (PDL) is a leading developer of humanized monoclonal antibodies. PDL's strategy is to leverage its technologies, expertise and intellectual property to become a profitable, research-based pharmaceutical company that manufactures innovative products to meet important medical needs and, in North America, markets its products and co-promotes those of certain of its partners. The Company's most advanced product, Zenapax[R] (daclizumab), has been approved for marketing in the United States (U.S.), Europe and several other countries for the prophylaxis of acute organ rejection in patients receiving renal transplantations. This product is exclusively licensed to Hoffmann-La Roche Inc. and its affiliates (Roche) and in 1998 the Company began receiving royalties from sales of Zenapax. PDL holds fundamental patents in the U.S., Europe and Japan for its antibody humanization technology and has signed license, option or humanization agreements covering more than 40 antibodies, over half of which are in clinical development. In addition to Zenapax, PDL receives royalty income from sales of two licensed antibodies: MedImmune's Synagis® (palivizumab) for prevention of a serious viral infection in infants and Genentech's Herceptin® for breast cancer. PDL also expects to receive royalty income from sales of Mylotarg™ (gemtuzumab ozogamicin), a licensed humanized antibody that was recently approved by the U.S. Food and Drug Administration for the treatment of certain patients with myeloid leukemia.

Activity:

- Manufacturing
- Research & Development

Product / Technology type(s) covered:

- Bio
- Reagents
- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active: North America , Europe , Asia

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: